体表面积和吉非替尼效果之间的关系： [, d! ~% k/ |* i1 z' Q! [: V g
http://abstracts2.asco.org/AbstView_132_112174.html) x6 H- s+ ~+ u5 H) [- ~
Impact of body surface area (BSA) on efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC).9 F5 P6 m' w3 D( T5 Z
Results: Median BSA of the subjects was 1.42 m2 (range: 0.98-1.95). At the cutoff level in BSA of 1.50 m2, overall survival (OS) and PFS in the large BSA group were not different from those in the small BSA group in the univariate analysis, which was also shown in multivariate analysis (hazard ratio: 1.12, 95% confidence interval: 0.66-1.92 and 1.67, 0.86-3.44, respectively). Among subjects with EGFR-mutant tumors (n=125; 81%), BSA had no association with OS, but patients with larger BSA had significantly worse PFS in the multivariate analysis (1.59, 1.01-2.51). The association of BSA with PFS was highly sensitive to increase or decrease in the cutoff level of BSA: BSA ≥ 1.45 m2 vs. <1.45 m2, [1.18, 0.80-1.75]; BSA ≥ 1.55 m2 vs. <1.55 m2, [1.75, 1.11-2.78]; BSA ≥ 1.60 m2 vs. <1.60 m2, [1.32, 0.82-2.11].Conclusions: In this cohort, PFS was significantly associated with BSA in EGFR-mutant NSCLC when BSA level was cut off by around the median score. Our findings might suggest the need for further investigation of dose finding PK/PD study stratified by BSA level in gefitinib therapy in EGFR-mutant NSCLC. |
显身卡
